FOLD * logo

Amicus Therapeutics BMV:FOLD * Stock Report

Last Price

Mex$208.80

Market Cap

Mex$58.4b

7D

0%

1Y

n/a

Updated

28 Apr, 2023

Data

Company Financials +

Amicus Therapeutics, Inc.

BMV:FOLD * Stock Report

Market Cap: Mex$58.4b

FOLD * Stock Overview

A biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. More details

FOLD * fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Amicus Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Amicus Therapeutics
Historical stock prices
Current Share PriceUS$208.80
52 Week HighUS$233.00
52 Week LowUS$208.80
Beta0.81
11 Month Change0%
3 Month Changen/a
1 Year Changen/a
33 Year Change-28.62%
5 Year Changen/a
Change since IPO-5.51%

Recent News & Updates

Recent updates

Shareholder Returns

FOLD *MX BiotechsMX Market
7D0%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how FOLD * performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how FOLD * performed against the MX Market.

Price Volatility

Is FOLD *'s price volatile compared to industry and market?
FOLD * volatility
FOLD * Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: FOLD * has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine FOLD *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002484Brad Campbellamicusrx.com

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases.

Amicus Therapeutics, Inc. Fundamentals Summary

How do Amicus Therapeutics's earnings and revenue compare to its market cap?
FOLD * fundamental statistics
Market capMex$58.36b
Earnings (TTM)-Mex$4.27b
Revenue (TTM)Mex$5.95b

9.8x

P/S Ratio

-13.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FOLD * income statement (TTM)
RevenueUS$329.23m
Cost of RevenueUS$38.60m
Gross ProfitUS$290.63m
Other ExpensesUS$527.20m
Earnings-US$236.57m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.83
Gross Margin88.28%
Net Profit Margin-71.85%
Debt/Equity Ratio318.6%

How did FOLD * perform over the long term?

See historical performance and comparison